Natalja Eigeliene
Overview
Explore the profile of Natalja Eigeliene including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
88
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vikstrom J, Shangin G, Viitanen T, Eigeliene N, Jekunen A
Pancreas
. 2022 Apr;
51(2):e18-e20.
PMID: 35404903
No abstract available.
2.
Karagiannis V, Wichmann V, Saarinen J, Eigeliene N, Andersen H, Jekunen A
Radiat Oncol
. 2022 Jan;
17(1):19.
PMID: 35093103
Background: Prostate cancer is the most common cancer among men, and its diagnosis and treatment are improving. Our study evaluated how PSMA-PET/CT prior to treatment planning might improve the optimal...
3.
Eigeliene N, Saarenheimo J, Wichmann V, Osterlund P, Jekunen A
Case Rep Oncol
. 2021 Dec;
14(3):1475-1482.
PMID: 34899239
In the era of personalized medicine, systemic treatment with chemotherapy in combination with targeted drugs, tailored according to and status, has improved the survival of patients with metastatic colorectal cancer...
4.
Saarenheimo J, Andersen H, Eigeliene N, Jekunen A
Front Oncol
. 2021 Oct;
11:754427.
PMID: 34712614
Decision-making in cancer treatment is part of clinicians' everyday work, and it is especially challenging in non-small cell lung cancer (NSCLC) patients, for whom decisions are clearly dependent on gene...
5.
Saarenheimo J, Andersen H, Eigeliene N, Jekunen A
World J Clin Oncol
. 2021 Sep;
12(8):656-663.
PMID: 34513599
Over the last twenty years, with the development of gene-driven therapies, numerous new drugs have entered clinical use. Very few of these new drugs are suitable for a large number...
6.
Saarenheimo J, Wahid N, Eigeliene N, Ravi R, Salomons G, Fernandez Ojeda M, et al.
Cancer Chemother Pharmacol
. 2021 Feb;
87(5):657-663.
PMID: 33544210
Capecitabine is a fluoropyrimidine that is widely used as a cancer drug for the treatment of patients with a variety of cancers. Unfortunately, early onset, severe or life-threatening toxicity is...
7.
Wichmann V, Eigeliene N, Saarenheimo J, Jekunen A
Acta Oncol
. 2020 Apr;
59(7):775-785.
PMID: 32275176
Metronomic dosing is used to give continuous chemotherapy at low doses. The low doses have minimal side effects and may enable cancer treatment to be remodeled toward the management of...
8.
Saarenheimo J, Eigeliene N, Andersen H, Tiirola M, Jekunen A
Front Oncol
. 2019 Mar;
9:129.
PMID: 30891428
Targeted therapies have allowed for an individualized treatment approach in non-small-cell lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy depend on genetic identification of personal tumor...
9.
Eigeliene N, Saarenheimo J, Jekunen A
Oncology
. 2019 Jan;
96(3):115-124.
PMID: 30654364
Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and...
10.
Bostrom P, Sainio A, Eigeliene N, Jokilammi A, Elenius K, Koskivuo I, et al.
Cancer Microenviron
. 2017 Jun;
10(1-3):39-48.
PMID: 28653173
Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer and has poor prognosis. In general, cancers are heterogeneous cellular masses comprised of different cell types and their...